The IFNα-Kinoïd is an anti interferon alpha (IFNα) therapeutic vaccine developed for the treatment of lupus (or Systemic Lupus Erythematosus, SLE).
Neovacs has shown that the self antibodies produced by administration of the IFNα-Kinoïd neutralize all 13 sub-types of IFNα in the serum of lupus patients. This breadth of activity supports the positioning of Neovacs’ therapeutic vaccine as a next-generation treatment for this disease.
A phase I/II clinical trial of IFNα-Kinoïd in lupus patient was conducted in 2010-2011. Very promising final results of the study were presented during the American College for Rheumatology Annual Meeting-Chicago in 2011 and published in 2013 in Arthritis & Rheumatology.
Neovacs is currently searching for potential partners to continue clinical development of IFNα-Kinoïd.
Lupus is a severe systemic and chronic autoimmune disease in which the immune system produces antibodies to cells within the body leading to widespread inflammation and tissue damage. Lupus primarily affects young women and can cause severe complications that necessitate aggressive therapies. There is currently no targeted therapy for lupus: only one new treatment has been granted market approval in this condition over the past 50 years.